Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 438-444

  Allen, P B ^a,b   Kamm, M A ^a,c,d   Peyrin Biroulet, L ^e   Studd, C ^a   Mc Dowell, C ^f   Allen, B C M ^b   Connell, W R ^a   De Cruz, P P ^a,c   Bell, S J ^a   Elliot, R P ^a   Brown, S ^a   Desmond, P V ^a   Lemann, M ^g   Colombel, J F ^h  

^a ST VINCENT S HOSPITAL   (Australia)

^b NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f Clinical Research Support Council NI   (United Kingdom)

^g HÔpital Necker Enfants Malades   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CRONBACH ALPHA COEFFICIENT; DISABILITY; ENTERITIS; FEMALE; HUMAN; INTERNAL CONSISTENCY; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; REPRODUCIBILITY; SHORT FORM 36; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; ULCERATIVE COLITIS;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84872680822     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12187     Document Type: Article

References (44)

1. Munkholm P, Langholz E, Davidsen M, Binder V,. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
2. Langholz E, Munkholm P, Davidsen M, Binder V,. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
3. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J,. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6.
4. Cosnes J, Cattan S, Blain A, et al,. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
5. Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ,. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 2003; 52: 1117-21.
6. Tourtelier Y, Dabadie A, Tron I, et al,. Incidence des maladies inflammatoires du tube digestif chez l'enfant en Bretagne (1994-1997). Association bretonne d'etude et de recherche sur les maladies de l'appareil digestif (Abermad). [Incidence of inflammatory bowel disease in children in Brittany (1994-1997). Breton association of study and research on digestive system diseases (Abermad)]. Arch Pediatr 2000; 7: 377-84.
7. Puntis J, McNeish AS, Allan RN,. Long term prognosis of Crohn's disease with onset in childhood and adolescence. Gut 1984; 25: 329-36.
8. Freeman HJ,. Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence. Can J Gastroenterol 2004; 18: 661-5.
9. Pigneur B, Seksik P, Viola S, et al,. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010; 16: 953-61.
10. Solberg IC, Lygren I, Jahnsen J, et al,. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
11. Solberg IC, Vatn MH, Hoie O, et al,. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
12. Loly C, Belaiche J, Louis E,. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
13. Felley C, Mottet C, Juillerat P, et al,. Fistulizing Crohn's disease. Digestion 2007; 76: 109-12.
14. Kamm MA, Ng SC,. Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol 2008; 6: 7-10.
15. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
16. Casellas F, Lopez-Vivancos J, Vergara M, Malagelada J,. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999; 17: 208-18.
17. Schnitzler F, Fidder H, Ferrante M, et al,. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
18. Mussell M, Bocker U, Nagel N, Singer MV,. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16: 1273-80.
19. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF,. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006; 23: 377-85.
20. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D,. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004; 19: 529-35.
21. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B,. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005; 11: 909-18.
22. Cieza A, Stucki G,. The international classification of functioning disability and health: its development process and content validity. Eur J Phys Rehabil Med 2008; 44: 303-13.
23. Mont D,. Measuring health and disability. Lancet 2007; 369: 1658-63.
24. Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S,. The definition of disability: what is in a name? Lancet 2006; 368: 1219-21.
25. Cieza A, Stucki A, Geyh S, et al,. ICF Core Sets for chronic ischaemic heart disease. J Rehabil Med 2004; 44 (Suppl.): 94-9.
26. Cieza A, Stucki G, Weigl M, et al,. ICF Core Sets for chronic widespread pain. J Rehabil Med 2004; 44 (Suppl): 63-8.
27. Stucki A, Stoll T, Cieza A, et al,. ICF Core Sets for obstructive pulmonary diseases. J Rehabil Med 2004; 44 (Suppl): 114-20.
28. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al,. Disability in inflammatory bowel diseases: developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflamm Bowel Dis 2010; 16: 15-22.
29. Lennard-Jones JE, Shivananda S,. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9: 353-9.
30. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD,. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
31. Guyatt G, Mitchell A, Irvine EJ, et al,. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10.
32. Best WR, Becktel JM, Singleton JW, Kern F Jr,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
33. Sutherland LR, Martin F,. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987; 32 (Suppl.): 64S-6S.
34. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al,. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61: 241-7.
35. Gibson TB, Ng E, Ozminkowski RJ, et al,. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008; 50: 1261-72.
36. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al,. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-13.
37. Calvet X, Motos J, Montserrat A, Gallardo O, Vergara M,. Analysis of court criteria for awarding disability benefits to patients with Crohn's disease. Clin Gastroenterol Hepatol 2009; 7: 1322-7.
38. Ananthakrishnan AN, Weber LR, Knox JF, et al,. Permanent work disability in Crohn's disease. Am J Gastroenterol 2008; 103: 154-61.
39. Timmer A,. How often and for how long are IBD patients expected to be sick, off work, or in hospital each year? Inflamm Bowel Dis 2008; 14 (Suppl. 2): S48-9.
40. Silverstein MD, Loftus EV, Sandborn WJ, et al,. Clinical course and costs of care for Crohn's disease: markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
41. Boonen A, Dagnelie PC, Feleus A, et al,. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis 2002; 8: 382-9.
42. Davidsen B, Munkholm P, Schlichting P, Nielsen OH, Krarup H, Bonnevie-Nielsen V,. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther 1995; 9: 75-9.
43. Sonnenberg A,. Disability from inflammatory bowel disease among employees in West Germany. Gut 1989; 30: 367-70.
44. Bernklev T, Jahnsen J, Henriksen M, et al,. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 402-12.